Advance Best- or First- in Class Candidates, Raise Capital & Drive Disease Modification
From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment.
Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering & Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting.
Who Attends This Differentiated Business Development Initiative?
- Global Pharma: Heads of Business Development, Search & Evaluation, and Asset Scouting for Neuroscience - comparing pipelines and enabling technologies to fuel future innovation.
- Innovative Biotech: C-level executives and BD leaders across neurodegeneration, psychiatry, neuro-oncology, and pain - seeking feedback, validation, and strategic partnerships with pharma and investors.
- Investors & Venture Capital: Leaders focused on neuroscience investments with higher risk appetite - looking for insights into pharma strategy and access to breakthrough opportunities.
Less competitive and more accessible, pharma can assess related programs back-to-back, while biotech has a protected opportunity to meet multiple big pharma players against the backdrop of market intelligence.
The focused niche really increased the impact for us overall. Thanks for including us in the program.
Executive Director, Business Development, Roche
It was stellar. I heard this sentiment echoed throughout. We appreciated the focused yet expansive discussions. The more intimate setting allowed for easier networking, too.”
Executive Director, Business Development, BMS
I thought it was fantastic - operationally excellent and thoughtfully designed.
Executive Director, Business Development, Merck
Explore the Full Event Guide
- 5 to 1 ratio of biotech to pharma and investors
- 30%+ acceptance rate on meeting platform
- Pharma and investors present in >50% of meetings
- Two formal structured networking sessions, one informal drinks reception
- Refine your strategy, strengthen your pitch, nurture your relationships to stay front-of-mind after JPM and before BIO
Attending Companies Include
Explore Related Events
Review the Program
Confidently evaluate if this targeted networking opportunity aligns with your partnering objectives. Review the format, speaker faculty and remaining presentation sessions in the full event guide.
Register to Join
Bridging the gap between innovative R&D and partnership conversations; deliberately timed between JPM and BIO. Register with earlybird discounts, secure a presentation opportunity whilst they remain, and share your company logo with us to advertise as attending on this website.
Become a Founding Partner
If you’re a law firm, or bank, or offer -omics, CRO or CDMO services and you’re looking for a differentiated and near exclusive opportunity to associate your brand awareness with high-value interactions, review information about becoming a founding partner here.